USPTO serial 87343488
AUREGEN BIOTHERAPEUTICS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- YAO, GRETTA
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AUREGEN BIOTHERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
Leigh Ann Lindquist SUGHRUE MION, PLLC2000 Pennsylvania Avenue, NW, Suite 900WASHINGTON, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for research purposes; stem cells for scientific purposes; stem cells for research or scientific purposes; stem cells other than for medical or veterinary purposes; hydrogel polymer edible coatings for tablets; lactic acid polymers; aqueous linear polymer gels; photo curable compositions comprising polymers; chemicals for use in polymerisations; engineered biological tissues and tissue arrays, namely, human and animal organ, connective, epithelial, muscular, and nervous tissues and tissue arrays, for use in scientific and medical research; biologically compatible materials, namely, hydrogels used to create polymeric networks used in the manufacture of living tissue; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment | ACTIVE | — |
| 005 | Pharmaceutical preparations for use in the field of 3D bio-printing of tissues and organs; preparations based on cellulous nano-fibrils for use in the 3D bio-printing of tissues and organs; tissue-regenerative pharmaceutical preparations; biological implants for skin and cartilage; biological skin and cartilage tissue for implantation; cells for medical use; human allograft tissue; living cells for medical use; implants of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials of living tissue for use in guided tissue regeneration; skin grafts; surgical implants comprised of living tissues; surgical implants of living tissues grown from stem cells; transdermal patches for use to create skin for prosthetic limbs and for skin grafts; living tissues for transplant; antibodies for use to create skin for prosthetic limbs and for skin grafts; stem cells for medical purposes; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, connective, epithelial, muscular, and nervous tissue and organs, for medical purposes; biological molecules to assist in the development of tissue; hemostatic gel matrix preparations for treating wounds; natural biomaterials for augmentation of bone, blood and tissue for medical purposes; processed human donor skin for the replacement of soft tissue; pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; pharmaceutical preparations for the treatment of bone diseases, for cartilaginous diseases, for vascular diseases, for neuronal degeneration, for degeneration of tendons and ligaments, for retinal degeneration, for renal degeneration, degeneration of soft tissue, for diseases with abnormal cell proliferation; natural biomaterials for bone filling; natural biomaterials for filling cartilage; stem cells for medical use; surgical implants of living tissue; surgical cloths for wound protection; surgical implants grown from stem cells; biological tissue cultures for medical use, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment | ACTIVE | — |
| 007 | Three-dimensional (3D) printers (3D printers); three-dimensional (3D) bioprinters (3D bioprinters); computerized equipment for the generation of three-dimensional shaped parts; machines for manufacturing three dimensional models, namely, computer-aided modeling devices; machines for manufacturing three dimensional (3D) living tissues; machines, namely, three dimensional (3D) bioprinter for the printing of living tissues; cartridges for containing printing material for use with three dimensional printers; cartridges for containing bioprinting material for use with three dimensional printers; printing cartridges for containing biomaterial for use with three dimensional printers; printing cartridges for containing bioink for use with three dimensional printers | ACTIVE | — |
| 009 | Laboratory apparatus for fabrication of three-dimensional tissues and organs; biochips for the production of three-dimensional living tissues and organs; bioreactor for cell culturing; bioreactors for laboratory use; bioreactors for research use; cell culture apparatus for laboratory use, namely, cell culture dishes, tissue culture flasks; imaging devices for use in research on biomaterials adapted and used for printing three- dimensional objects for the creation of prosthetic limbs and grafts; laboratory apparatus and instruments for use in research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts; print heads for inkjet printers; scientific research and laboratory apparatus and instruments for research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts in the field of cytology; laboratory apparatus and instruments for research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts for use in biopharmaceutical discovery and development; laboratory apparatus and instruments for research on biomaterials adapted and used for printing three-dimensional objects for the creation of prosthetic limbs and grafts; replacement parts and fittings for all the aforesaid goods; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment | ACTIVE | — |
| 010 | Surgical, medical, dental apparatus and instruments, including imaging devices, for medical purposes; orthopedic articles, namely, burrs, picks, mirrors, tissue cutters, support bandages, and braces; artificial limbs; artificial surgical implants; bone substitutes for surgical use; fluid injectors for medical purposes; trocars; artificial tissue replacement for restoring, maintaining and /or improving the function of diseased or damaged human or animal tissue; synthetic implants and transplants and synthetic modified implants and transplants, tissue, cells and/or molecules for replacing and/or for supporting the function of missing or damaged body parts; synthetic hard and soft tissue, in particular synthetic bone for transplantation purposes, synthetic bone replacement, cartilage replacement, vessel replacement, tissue replacement and fatty tissue replacement; synthetic modified implants and transplants with endogenous material, tissue, cells or molecules for replacement and/or for supporting the function of missing or damaged body parts, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment | ACTIVE | — |
| 040 | 3D printing services; renting of 3D printers; creation of customized three-dimensional shaped parts using rapid prototyping equipment; 3D bioprinting; bioprinting | ACTIVE | — |
| 042 | Technical research in the fields of biomimetics, biomaterials, material adaptation, 3D bioprinting and tissue engineering; research and development of medical devices; research in the field of nanotechnology and nanomaterials; synthetic biology research; robotics research; bioengineering research; nanotherapeutics research; 3D bioprinting research; tissue engineering research; research and development of 3D technology and processes; development of rapid prototyping equipment; technical consultancy relating to rapid prototyping; scientific research consulting in the fields of three-dimensional printing; scientific services relating to the isolation and cultivation of human tissues and cells; scientific and medical research and development in the field of bio-printing; scientific and medical research and development in the field of tissue manufacturing; development and culture of artificial tissues and cells (tissue engineering); tissue engineering services; industrial analysis and research services in the field of tissue engineering research in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals, research and testing services in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals; research and development of new products for others in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals; design and development of computer hardware and software, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment | ACTIVE | — |
| 044 | Medical services, namely, in the field of gene and cellular immunotherapies and transplantation, monitoring and reporting services; medical treatment services; consulting services in the fields of medical treatment and medicines; human cell and tissue banking services; collection and preservation of human blood and cells for medical use, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Auregen BioTherapeutics SA
- Other trademarks owned by Auregen BioTherapeutics SA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 007
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AUREGEN BIOTHERAPEUTICS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 16, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 15, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 4, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 3, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 26, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| May 26, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 19, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 19, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 19, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 19, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| May 19, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 19, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 19, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 1, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 30, 2019 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 30, 2019 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 30, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 3, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 1, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 1, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 1, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 17, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 19, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 17, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 17, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 17, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 8, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 6, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 6, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 6, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 14, 2018 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 6, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 21, 2018 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jan 9, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 14, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 14, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 25, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 5, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 5, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 5, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 5, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 5, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 25, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 25, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 25, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2017 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Sep 5, 2017 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Aug 18, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 9, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 9, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 9, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 23, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 23, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 23, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 16, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| May 11, 2017 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| May 3, 2017 | ALIE | ASSIGNED TO LIE | — |
| Apr 18, 2017 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 28, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 24, 2017 | NWAP | NEW APPLICATION ENTERED | — |